Form 4: Novo Holdings A/S Reduces Stake in IO Biotech, Inc.

Novo Holdings A/S, a 10% owner of IO Biotech, Inc., sold shares of common stock in two transactions on July 25 and July 26, 2024.

Summary

• Novo Holdings A/S, a 10% owner of IO Biotech, Inc., filed a Form 4 detailing changes in beneficial ownership.
• On July 25, 2024, Novo Holdings sold 51,522 shares of common stock at a weighted average price of $1.3264 per share.
• These shares were sold in multiple transactions with prices ranging from $1.29 to $1.39.
• On July 26, 2024, Novo Holdings sold 23,478 shares of common stock at a weighted average price of $1.3113 per share.
• These shares were sold in multiple transactions with prices ranging from $1.28 to $1.34.
• Following these transactions, Novo Holdings directly owns 4,354,449 shares of IO Biotech, Inc.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative as a major shareholder is reducing their position. This could create selling pressure, but the reasons for the sale are not disclosed and may not be related to the company's performance.

Negatives

• Novo Holdings A/S reduced its stake in IO Biotech, Inc., which could be perceived negatively by investors.

Risks

• Continued selling pressure from Novo Holdings could further depress the stock price of IO Biotech, Inc.

Industry Context

Sales of shares by major holders are common and can be for a variety of reasons, not necessarily indicative of the company's performance.

Stakeholder Impact

• Shareholders may react to the news of Novo Holdings selling shares, potentially impacting the stock price.

Key Dates